# Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

> **NCT00265889** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 42 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** busulfan
- **DRUG:** cyclophosphamide
- **DRUG:** etoposide
- **DRUG:** melphalan
- **PROCEDURE:** autologous-autologous tandem hematopoietic stem cell transplantation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00265889
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2013-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00265889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00265889, "Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00265889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*